Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Total Enrollment
115 participants
Study Classification
OBSERVATIONAL
Study Start Date
2023-06-01
Study Completion Date
2027-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Objective: To identify known and unknown bacterial pathogens in patients with pleural infections using a combination of conventional culture and next-generation sequencing approaches.
Hypothesis to be tested: The investigators hypothesize that next-generation sequencing will serve as a comprehensive approach to identify culturable and unculturable bacterial pathogens in patients with pleural infections compared to the conventional culture.
Design and subjects: This is a prospective cohort study to be conducted in the medical department of a tertiary care hospital in Hong Kong involving patients with pleural infection. Patients will be recruited if a pleural infection is suspected, with pleural fluid sampled and a 6-month follow-up. The clinical management by the medical team will not be interfered.
Study instruments: Pleural fluid will be collected for conventional culture, 16S amplicon and shotgun metagenomic sequencing in parallel. The clinical information will be collected to clarify the causative correlation between symptoms, clinical outcomes and pathogen infections.
Main outcome measures: The full spectrum of causative bacteria in pleural infection will be characterized. The diagnostic performance of identifying causative bacteria in pleural infection will be compared between the studied methods. The antimicrobial resistance pattern, clinical outcomes of pleural infection will also be compared between groups as categorized by the pattern of bacteriology identified by different methods.
Data analysis: With reference to the conventional culture as the gold standard, sensitivity, specificity, positive predictive values and negative predictive values of 16S ribosomal ribonucleic acid (rRNA) gene amplicon and shotgun metagenomic sequencing will be calculated.
Hypothesis to be tested: The investigators hypothesize that next-generation sequencing will serve as a comprehensive approach to identify culturable and unculturable bacterial pathogens in patients with pleural infections compared to the conventional culture.
Design and subjects: This is a prospective cohort study to be conducted in the medical department of a tertiary care hospital in Hong Kong involving patients with pleural infection. Patients will be recruited if a pleural infection is suspected, with pleural fluid sampled and a 6-month follow-up. The clinical management by the medical team will not be interfered.
Study instruments: Pleural fluid will be collected for conventional culture, 16S amplicon and shotgun metagenomic sequencing in parallel. The clinical information will be collected to clarify the causative correlation between symptoms, clinical outcomes and pathogen infections.
Main outcome measures: The full spectrum of causative bacteria in pleural infection will be characterized. The diagnostic performance of identifying causative bacteria in pleural infection will be compared between the studied methods. The antimicrobial resistance pattern, clinical outcomes of pleural infection will also be compared between groups as categorized by the pattern of bacteriology identified by different methods.
Data analysis: With reference to the conventional culture as the gold standard, sensitivity, specificity, positive predictive values and negative predictive values of 16S ribosomal ribonucleic acid (rRNA) gene amplicon and shotgun metagenomic sequencing will be calculated.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Next-generation Sequencing Technology in the Clinical Application of Respiratory Specimens
NCT07191080
Lung Infection
ENROLLING_BY_INVITATION
mNGS for Detection of Pathogens for Pulmonary Infection
NCT03798925
Pulmonary Infection
UNKNOWN
The Value of mNGS in Diagnosis of Pulmonary Infection
NCT06307405
Pulmonary Infection
NOT_YET_RECRUITING
Metagenomic NGS for Diagnosis of Pneumonia
NCT05979350
Pneumonia
Diagnosis
ACTIVE_NOT_RECRUITING
NA
The Microbiology of Pleural Infection
NCT04569110
Pleural Infection
Pleural Infection Bacterial
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Parapneumonic effusion (PPE) is a common and serious clinical problem. Among patients suffering from community-acquired pneumonia, up to 57% of them would develop parapneumonic effusion (PPE), and 7.2% would develop complicated parapneumonic effusion (CPPE) and empyema. The latter two, collectively known as pleural infection, are associated with long hospital stay, high Intensive Care Unit admission rates, serious morbidity and mortality.
The cornerstone of treating pleural infection is the timely administration of appropriate antibiotics and adequate pleural fluid drainage. However, the initial choice of antibiotics is almost always empirical, and only able to be adjusted upon the return of positive microbiological results from the pleural fluid or relevant specimens. Indeed, the inadequate understanding of local bacteriology, drug resistance pattern and the lack of local guidance on empirical antibiotic coverage for pleural infection have led to heterogeneous prescription behaviour of antibiotics, which is a significant risk factor of the emergence of drug resistance (e.g., increasing incidence of methicillin-resistant Staphylococcus aureus), complications of antibiotic therapies (e.g., Clostridium difficile infections) and adverse patient outcomes.
Conventional culture of pleural effusion has been considered as an essential part of the treatment algorithm, but it carries two critical disadvantages that may limit clinical care:
1. Long turnaround time Although the Gram stain results can usually be available within one day, the final culture results and antimicrobial sensitivity pattern only return after up to five days. In case the pleural infection is not under control while waiting for the culture results, physicians would blindly escalate the coverage of antibiotics or proceed to additional pleural interventions, which may be avoidable if the microbiological results can be available early. The delayed return of drug sensitivity pattern may lead to the initial use of discordant antibiotics, which happened in 17 to 24% of patients in two local cohorts
2. Negative pleural fluid culture is common in pleural infection Up to 40% of pleural fluid in pleural infection failed to reveal any microorganism by conventional culture, due to a failure to culture fastidious organisms and antibiotics treatment before pleural fluid sampling. Our study group has found that 88% of patients with empyema received empirical antibiotics before any pleural intervention, which reflected the real-world practice. Although inoculating pleural fluid into a blood culture bottle may increase the culture yield in pleural infection by 20%, it is still far from satisfactory in clinical practice. In addition, the microbiological workup of non-respiratory specimens is frequently not informative. Thus, the use of antibiotics throughout the treatment course is purely empirical in those patients with culture-negative pleural infection. To overcome this problem and the often polymicrobial nature of the infections, very broad-spectrum agents are currently advocated. On the contrary, a lack of bacterial culture information with inadequate antibiotic coverage has been associated with an increased mortality rate.
Non-culture molecular studies have been applied to overcome the insufficiencies of conventional culture in the past decade, to characterize the spectrum of bacteria in pleural infection and the antibiotic resistance pattern within a short period of time and inform correct clinical decisions. Multiplex PCR (polymerase chain reaction) sequencing with a pneumonia panel is able to identify bacteria that are commonly involved in pneumonia. However, the aetiology of pleural infection is not completely a replicate of community-acquired pneumonia, and thus limit its utility. 16S ribosomal ribonucleic acid (rRNA) gene sequencing outperforms the conventional culture method by identifying more bacteria, especially anaerobes, in the pleural fluid. It provides a high-throughput and cost-efficient solution to screen the microbiota community for clinical samples with low bacterial biomass and/or high host genomic contamination. However, it has a limitation in detecting microbiome at the species level and may introduce PCR-biases that mask the true community composition. Dyrhovden R et al performed the first metagenomic sequencing analysis in Norway to understand the spectrum of bacteriology in confirmed empyema. They identified 385 bacterial detections, whereas culture detected 38 (10%) and 16S rRNA gene PCR/Sanger-based sequencing detected 87 (23%) in 64 patients with empyema. Such findings confirmed the disadvantage of the conventional culture method and broader coverage of antibiotics is required for the treatment of pleural infection. However, this metagenomic study was retrospective in nature, covered patients with empyema only and did not reflect the full spectrum of pleural infection. Chen et al employed a metagenomic sequencing study with functional analysis and identified two distinct microbiome clusters in pleural infection, Staphylococcus aureus as the core species (HA-SA type) and a more diverse microbial community (LA-SA type), which is different from the usual bacteriology pattern found in Hong Kong studies. They also identified the resistome of bacteria, including tetracycline and beta-lactam resistance, which is important to guide the appropriate antibiotic regimen in the initial treatment phase. The interpretation of these two studies was limited because the authors did not correlate the microbiological results with patient clinical outcomes. Recently, Kanellakis et al confirmed the predominantly polymicrobial nature of pleural infection by 16S rRNA metagenomic sequencing analysis, with a diverse bacterial spectrum. They also identified a distinct bacteriology spectrum in polymicrobial and monomicrobial cases and correlated the bacteriology with clinical outcomes.
Given the fact that geographical differences in bacteriology of pleural infection may exist and previous studies did not translate the modern molecular sequencing technologies in refining the initial antibiotic use, a local prospective study linking the laboratory and clinical findings using broader metagenomic sequencing methods is desired. We hypothesize that the 16S rRNA gene amplicon and shotgun metagenomic sequencing has a higher detection rate of bacteria in the pleural fluid and identification of antibiotic resistance patterns than conventional culture in patients with pleural infection. The results from the two molecular sequencing methods are complementary and can guide the initial antibiotic treatment, minimize the emergence of drug resistance, correlate the microbiological spectrum with the clinical outcomes and prepare for a large-scale territory-wide study by incorporating molecular technology into the management of pleural infection. The short turnaround time also makes this technology attractive to physicians and ultimately benefits the patient by improving the quality of care. As the diagnostic performance, technical requirements and cost of the two molecular sequencing methods are different, this study will provide fundamental information and guide their use in clinical settings.
The pathogenesis of community-acquired pleural infection is controversial. The conventional belief of transmigration of bacterial through the lung parenchyma to the pleural cavity was challenged by (1) different spectrum of causative pathogens for pneumonia and pleural infection, (2) the absence of radiological evidence of pneumonia, and (3) anaerobes are frequently found in pleural fluid culture but are uncommon in normal lung parenchyma because of high oxygen tension. Therefore, understanding the ultimate source of pathogens and understand their route of entering the pleural space is a critical step in preventing and treating pleural infection. Currently, there is very limited evidence associating the microbiota in pleural fluid of pleural infection, and those in the oral cavity and gastrointestinal tract.
The aim of the study is to characterize the full spectrum of causative bacteria in pleural infection and compare the diagnostic performance of identifying the pathogens between conventional culture, 16S rRNA gene amplicon and shotgun metagenomic sequencing. The antimicrobial resistance pattern of causative bacteria, clinical outcomes of pleural infection will also be compared between groups as categorized by the pattern of bacteriology identified by different methods.
The cornerstone of treating pleural infection is the timely administration of appropriate antibiotics and adequate pleural fluid drainage. However, the initial choice of antibiotics is almost always empirical, and only able to be adjusted upon the return of positive microbiological results from the pleural fluid or relevant specimens. Indeed, the inadequate understanding of local bacteriology, drug resistance pattern and the lack of local guidance on empirical antibiotic coverage for pleural infection have led to heterogeneous prescription behaviour of antibiotics, which is a significant risk factor of the emergence of drug resistance (e.g., increasing incidence of methicillin-resistant Staphylococcus aureus), complications of antibiotic therapies (e.g., Clostridium difficile infections) and adverse patient outcomes.
Conventional culture of pleural effusion has been considered as an essential part of the treatment algorithm, but it carries two critical disadvantages that may limit clinical care:
1. Long turnaround time Although the Gram stain results can usually be available within one day, the final culture results and antimicrobial sensitivity pattern only return after up to five days. In case the pleural infection is not under control while waiting for the culture results, physicians would blindly escalate the coverage of antibiotics or proceed to additional pleural interventions, which may be avoidable if the microbiological results can be available early. The delayed return of drug sensitivity pattern may lead to the initial use of discordant antibiotics, which happened in 17 to 24% of patients in two local cohorts
2. Negative pleural fluid culture is common in pleural infection Up to 40% of pleural fluid in pleural infection failed to reveal any microorganism by conventional culture, due to a failure to culture fastidious organisms and antibiotics treatment before pleural fluid sampling. Our study group has found that 88% of patients with empyema received empirical antibiotics before any pleural intervention, which reflected the real-world practice. Although inoculating pleural fluid into a blood culture bottle may increase the culture yield in pleural infection by 20%, it is still far from satisfactory in clinical practice. In addition, the microbiological workup of non-respiratory specimens is frequently not informative. Thus, the use of antibiotics throughout the treatment course is purely empirical in those patients with culture-negative pleural infection. To overcome this problem and the often polymicrobial nature of the infections, very broad-spectrum agents are currently advocated. On the contrary, a lack of bacterial culture information with inadequate antibiotic coverage has been associated with an increased mortality rate.
Non-culture molecular studies have been applied to overcome the insufficiencies of conventional culture in the past decade, to characterize the spectrum of bacteria in pleural infection and the antibiotic resistance pattern within a short period of time and inform correct clinical decisions. Multiplex PCR (polymerase chain reaction) sequencing with a pneumonia panel is able to identify bacteria that are commonly involved in pneumonia. However, the aetiology of pleural infection is not completely a replicate of community-acquired pneumonia, and thus limit its utility. 16S ribosomal ribonucleic acid (rRNA) gene sequencing outperforms the conventional culture method by identifying more bacteria, especially anaerobes, in the pleural fluid. It provides a high-throughput and cost-efficient solution to screen the microbiota community for clinical samples with low bacterial biomass and/or high host genomic contamination. However, it has a limitation in detecting microbiome at the species level and may introduce PCR-biases that mask the true community composition. Dyrhovden R et al performed the first metagenomic sequencing analysis in Norway to understand the spectrum of bacteriology in confirmed empyema. They identified 385 bacterial detections, whereas culture detected 38 (10%) and 16S rRNA gene PCR/Sanger-based sequencing detected 87 (23%) in 64 patients with empyema. Such findings confirmed the disadvantage of the conventional culture method and broader coverage of antibiotics is required for the treatment of pleural infection. However, this metagenomic study was retrospective in nature, covered patients with empyema only and did not reflect the full spectrum of pleural infection. Chen et al employed a metagenomic sequencing study with functional analysis and identified two distinct microbiome clusters in pleural infection, Staphylococcus aureus as the core species (HA-SA type) and a more diverse microbial community (LA-SA type), which is different from the usual bacteriology pattern found in Hong Kong studies. They also identified the resistome of bacteria, including tetracycline and beta-lactam resistance, which is important to guide the appropriate antibiotic regimen in the initial treatment phase. The interpretation of these two studies was limited because the authors did not correlate the microbiological results with patient clinical outcomes. Recently, Kanellakis et al confirmed the predominantly polymicrobial nature of pleural infection by 16S rRNA metagenomic sequencing analysis, with a diverse bacterial spectrum. They also identified a distinct bacteriology spectrum in polymicrobial and monomicrobial cases and correlated the bacteriology with clinical outcomes.
Given the fact that geographical differences in bacteriology of pleural infection may exist and previous studies did not translate the modern molecular sequencing technologies in refining the initial antibiotic use, a local prospective study linking the laboratory and clinical findings using broader metagenomic sequencing methods is desired. We hypothesize that the 16S rRNA gene amplicon and shotgun metagenomic sequencing has a higher detection rate of bacteria in the pleural fluid and identification of antibiotic resistance patterns than conventional culture in patients with pleural infection. The results from the two molecular sequencing methods are complementary and can guide the initial antibiotic treatment, minimize the emergence of drug resistance, correlate the microbiological spectrum with the clinical outcomes and prepare for a large-scale territory-wide study by incorporating molecular technology into the management of pleural infection. The short turnaround time also makes this technology attractive to physicians and ultimately benefits the patient by improving the quality of care. As the diagnostic performance, technical requirements and cost of the two molecular sequencing methods are different, this study will provide fundamental information and guide their use in clinical settings.
The pathogenesis of community-acquired pleural infection is controversial. The conventional belief of transmigration of bacterial through the lung parenchyma to the pleural cavity was challenged by (1) different spectrum of causative pathogens for pneumonia and pleural infection, (2) the absence of radiological evidence of pneumonia, and (3) anaerobes are frequently found in pleural fluid culture but are uncommon in normal lung parenchyma because of high oxygen tension. Therefore, understanding the ultimate source of pathogens and understand their route of entering the pleural space is a critical step in preventing and treating pleural infection. Currently, there is very limited evidence associating the microbiota in pleural fluid of pleural infection, and those in the oral cavity and gastrointestinal tract.
The aim of the study is to characterize the full spectrum of causative bacteria in pleural infection and compare the diagnostic performance of identifying the pathogens between conventional culture, 16S rRNA gene amplicon and shotgun metagenomic sequencing. The antimicrobial resistance pattern of causative bacteria, clinical outcomes of pleural infection will also be compared between groups as categorized by the pattern of bacteriology identified by different methods.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Parapneumonic Effusion
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
CASE_CONTROL
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Parapneumonic effusion
Patients with parapneumonic effusion
16S rRNA gene amplicon sequencing
Intervention Type
DIAGNOSTIC_TEST
molecular sequencing for the microbiome in parapneumonic effusion
Non-parapneumonic effusion
Patients with pleural effusion but not parapneumonic in nature
16S rRNA gene amplicon sequencing
Intervention Type
DIAGNOSTIC_TEST
molecular sequencing for the microbiome in parapneumonic effusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
16S rRNA gene amplicon sequencing
molecular sequencing for the microbiome in parapneumonic effusion
Intervention Type
DIAGNOSTIC_TEST
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Shotgun metagenomic sequencing
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients hospitalized for suspected pleural infection, irrespective of community-acquired or hospital-acquired in nature
* Pleural tapping will be performed for pleural fluid analysis
* Chinese ethnicity
* Aged 18 years old or above
* Pleural effusion is not related to any infection including pneumonia (e.g. malignancy, fluid overload)
* Pleural tapping will be performed for pleural fluid analysis
* Chinese ethnicity
* Aged 18 years old or above
* Pleural tapping will be performed for pleural fluid analysis
* Chinese ethnicity
* Aged 18 years old or above
* Pleural effusion is not related to any infection including pneumonia (e.g. malignancy, fluid overload)
* Pleural tapping will be performed for pleural fluid analysis
* Chinese ethnicity
* Aged 18 years old or above
Exclusion Criteria
* Use of antibiotics for more than 24 hours for the current episode of infection
* On long-term local or systemic antibiotics
* Tuberculous pleuritis
* Pregnant or lactating women
* Failed to obtain informed consent due to patient's refusal or cognitive impairment
Control group (patients with effusions but not parapneumonic in nature)
* The use of systemic (including oral and intravenous) and inhaled antibiotics in the past 1 month
* On long-term local or systemic antibiotics
* Tuberculous pleuritis
* Pregnant or lactating women
* Failed to obtain informed consent due to patient's refusal or cognitive impairment
* On long-term local or systemic antibiotics
* Tuberculous pleuritis
* Pregnant or lactating women
* Failed to obtain informed consent due to patient's refusal or cognitive impairment
Control group (patients with effusions but not parapneumonic in nature)
* The use of systemic (including oral and intravenous) and inhaled antibiotics in the past 1 month
* On long-term local or systemic antibiotics
* Tuberculous pleuritis
* Pregnant or lactating women
* Failed to obtain informed consent due to patient's refusal or cognitive impairment
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese University of Hong Kong
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ka Pang Chan
Doctor (Clinical Lecturer)
Responsibility Role
PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chinese University of Hong Kong
Hong Kong, , Hong Kong
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Hong Kong
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PPE_Metagenomic
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Microbiome and Host Susceptibility in Severe Pneumonia, a Prospective, Multicenter, Cohort Study
NCT06114784
RECRUITING
The Predictive Value of Molecular Diagnostic Techniques in the Antimicrobial- Resistance Phenotypes of Pathogens
NCT07035535
ENROLLING_BY_INVITATION
Chinese Hospital Acquired Pneumonia Collaboration Network: Epidemiology, Diagnosis and Treatment
NCT06028217
NOT_YET_RECRUITING
Diagnostic Utility of Pleural Infection-specific Multiplex PCR Panel
NCT07077096
NOT_YET_RECRUITING
M-ROSE Combined With mNGS in Severe Hospital-acquired Pneumonia
NCT05300776
UNKNOWN
NA
Nutritional Assessment in Non-tuberculous Mycobacteria Pulmonary Disease
NCT05376280
RECRUITING
Dynamic Pattern of Etiology, Immunoinflammatory Factors and Their Association With Prognosis of Severe Pneumonia
NCT06538441
ACTIVE_NOT_RECRUITING
A Retrospective Study Investigating the Factors Related to Non-tuberculous Mycobacterial Pulmonary Disease in Hong Kong
NCT04538898
UNKNOWN
Diagnostic and Prognostic Value of Lung Microbiota in Early Lung Infection After Lung Transplantation
NCT05627505
UNKNOWN
Respiratory Virus Metagenomics After COVID-19
NCT05126589
RECRUITING
Urinary Antigen Test for Stretococcus Pneumoniae Serotype Prevalence in Community Acquired Pneumonia
NCT05374018
RECRUITING
Rapid Diagnosis of Severe Respiratory Tract Infectious Diseases and Screening of Biomarkers for Stratified Diagnosis
NCT06533514
NOT_YET_RECRUITING
Pathogenic Microorganisms in Adult Severe Pneumonia Patients
NCT04433403
UNKNOWN
Analysis of the Pulmonary Microbiome
NCT06274931
RECRUITING
Metagenomic Sequencing in Clinical Infectious Diseases
NCT05353634
COMPLETED
A Molecular Toolkit for the Microbial Investigation of Severe Community Acquired Pneumonia
NCT02963142
COMPLETED
Molecular Diagnosis and Prognosis of Severe Pulmonary Infection Immunosuppressed Hosts
NCT04395066
UNKNOWN
Effects of Neutrophil Extracellular Traps and Damage-associated Molecular Pattern Molecules on Long Term Use of Macrolides in Adults With Chronic Respiratory Disease
NCT05575726
UNKNOWN
Rapid Identification of Infectious Pathogens in Severe Pneumonia Guided by Bronchoscopic Imaging and Lung CT
NCT07308340
NOT_YET_RECRUITING
Microbial Colonization Distribution and Adaptive Evolution of Lower Respiratory Tract in Bronchiectasis Patients.
NCT04966793
RECRUITING
Evaluation of Streptococcus Pneumoniae Serotypes Prevalence Using a Urinary Kit
NCT04647630
RECRUITING
Detect Novel Pathogens and Characterize Emerging Infections
NCT01979705
UNKNOWN
Early Identification and Severity Prediction of Acute Respiratory Infectious Disease
NCT04955756
UNKNOWN
NA